Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2012 3
2014 1
2015 1
2017 1
2018 1
2021 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK, Bista A, Shafii B. Shah BK, et al. Anticancer Res. 2014 Sep;34(9):5117-20. Anticancer Res. 2014. PMID: 25202101
PATIENTS AND METHODS: We selected patients with advanced diffuse large B-cell lymphoma from the Surveillance, Epidemiology, and End RESULTS (SEER) 18 database, and calculated relative survival rates for patients diagnosed from 2002-2005 ( …
PATIENTS AND METHODS: We selected patients with advanced diffuse large B-cell lymphoma from the Su …
Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma.
Gouni S, Strati P, Toruner G, Aradhya A, Landgraf R, Bilbao D, Vega F, Agarwal NK. Gouni S, et al. Leuk Lymphoma. 2022 Jun;63(6):1302-1313. doi: 10.1080/10428194.2021.2020782. Epub 2021 Dec 31. Leuk Lymphoma. 2022. PMID: 34969327
Here, we retrospectively reviewed patients with naive-treated advanced diffuse large B-cell lymphoma (DLBCL) receiving frontline R-CHOP, and for whom data regarding differential statins use was available at the time of initiation of treat …
Here, we retrospectively reviewed patients with naive-treated advanced diffuse large B-cell lymphoma …
Development and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphoma.
Wan M, Zhang W, Huang H, Fang X, Chen Y, Tian Y, Yao Y, Weng H, Chen Z, Yu L, Tian Y, Huang H, Li X, Hong H, Lin T. Wan M, et al. Clin Exp Med. 2024 Mar 30;24(1):64. doi: 10.1007/s10238-024-01326-y. Clin Exp Med. 2024. PMID: 38554186 Free PMC article.
Advanced diffuse large B cell lymphoma (DLBCL) is a common malignant tumor with aggressive clinical features and poor prognosis. ...The independent prognostic factors were included in the nomogram, and the nomogram to predict the p …
Advanced diffuse large B cell lymphoma (DLBCL) is a common malignant tumor with aggressive clinica …
Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma.
Milanovic N, Matkovic S, Ristic D, Jelic S, Petrovic M. Milanovic N, et al. J BUON. 2012 Jul-Sep;17(3):497-501. J BUON. 2012. PMID: 23033288
PURPOSE: Lactate dehydrogenase (LDH) and beta-2 microglobulin (B2M) are incorporated in the so-called "serologic staging system", as independent parameters for predicting time to treatment failure (TTF) and overall survival (OS) for aggressive non-Hodgkin's lymphoma (NHL) …
PURPOSE: Lactate dehydrogenase (LDH) and beta-2 microglobulin (B2M) are incorporated in the so-called "serologic staging system", as indepen …
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.
Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP. Stopeck AT, et al. Blood. 2012 Aug 9;120(6):1210-7. doi: 10.1182/blood-2012-04-423079. Epub 2012 Jun 25. Blood. 2012. PMID: 22734071 Free PMC article. Clinical Trial.
S0515 was a phase 2 trial to determine whether the addition of bevacizumab to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) plus rituximab (R-CHOP) would improve progression-free survival (PFS) without adding significant toxicity in patients with newly diagnosed …
S0515 was a phase 2 trial to determine whether the addition of bevacizumab to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) …
Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based Study.
Fluge Ø, Mannsåker B, Torp A, Mjaaland I, Helgeland L, Klos J, Mella O, Berentsen S, Meyer P. Fluge Ø, et al. Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):125-135.e3. doi: 10.1016/j.clml.2017.12.002. Epub 2017 Dec 24. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29352718 Free article.
BACKGROUND: The role of consolidative radiotherapy (RT) in advanced diffuse large B-cell lymphoma (DLBCL) is not established. ...The use of RT was significantly different: 17 patients (23%) received RT at SUS and 92 patients (65%) at HUS …
BACKGROUND: The role of consolidative radiotherapy (RT) in advanced diffuse large B-cell lymphoma …
Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma.
Yamauchi T, Matsuda Y, Takai M, Tasaki T, Tai K, Hosono N, Negoro E, Ikegaya S, Takagi K, Kishi S, Yoshida A, Urasaki Y, Iwasaki H, Ueda T. Yamauchi T, et al. Anticancer Res. 2012 Nov;32(11):5051-7. Anticancer Res. 2012. PMID: 23155278
The clinical significance of serum soluble interleukin-2 receptor (sIL2R) levels was retrospectively assessed in patients with advanced diffuse large B-cell lymphoma (DLBCL). Twenty-one patients, who were newly-diagnosed with advanced DLB …
The clinical significance of serum soluble interleukin-2 receptor (sIL2R) levels was retrospectively assessed in patients with advanced …
Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D, Miura K, Nakagawa M, Ohtake S, Sakagami M, Uchino Y, Takahashi H, Kiso S, Hojo A, Kodaira H, Yagi M, Hirabayashi Y, Kobayashi Y, Iriyama N, Kobayashi S, Hatta Y, Kura Y, Sugitani M, Takei M. Kurita D, et al. Int J Hematol. 2015 Jun;101(6):585-93. doi: 10.1007/s12185-015-1780-6. Epub 2015 Mar 17. Int J Hematol. 2015. PMID: 25776837
Major adverse events included hematological toxicities, but there were no treatment-related deaths during the observation period. We conclude that the R-D-CHOP regimen followed by HDC/ASCT or HD-MTX is a promising treatment option for younger patients with highly advanced …
Major adverse events included hematological toxicities, but there were no treatment-related deaths during the observation period. We …
Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas.
Ferreri AJ, Dell'Oro S, Reni M, Ceresoli GL, Cozzarini C, Ponzoni M, Villa E. Ferreri AJ, et al. Oncology. 2000 Apr;58(3):219-26. doi: 10.1159/000012104. Oncology. 2000. PMID: 10765124
BACKGROUND: To assess the impact on survival of consolidation radiotherapy to bulky or semibulky lesions in patients with advanced diffuse large B cell lymphoma (DLCL) in complete remission after primary chemotherapy. ...Multivariate anal …
BACKGROUND: To assess the impact on survival of consolidation radiotherapy to bulky or semibulky lesions in patients with advanced …